Redruth, United Kingdom

  • A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

    Phase

    3

    Span

    314 weeks

    Sponsor

    Eli Lilly and Company

    Redruth, Cornwall

    Recruiting

  • Anti-psychotic Drug Prescribing Patterns Within Specialist Adult ID Services in England and Wales

    Feasibility protocol objectives: 1. Is it feasible to identify People with Intellectual Disabilities (PwID) who have been prescribed 2 or more anti-psychotic medications over 7 years retrospectively. 2. It is possible to obtain a complete data set for each patient identified and therefore be able to explore the prescribing patterns across the eight sites. 3. Is it feasible to quantify anti-psychotic treatment (APT) prescribing in PwID as chlorpromazine equivalent dose values across different healthcare Trusts in England and Wales. Main objectives: 4. To explore yearly and overall prescribing patterns among PwID (with or without mental-health reasons (psychiatric co-morbidities)) in receipt of ≥2 forms of anti-psychotic treatment (multiple) over time? 5. How has multiple anti-psychotic treatment prescribing changed between 2017 and 2023 using chlorpromazine equivalent dose values, in PwID with mental health and no mental health indications? 6. What has been the impact of the COVID-19 pandemic (and corresponding lockdown restrictions in England and Wales) on multiple anti-psychotic treatment prescribing among PwID? 7. Can the NHS England Statistical Process Control tool (SPC) be utilised to track yearly anti-psychotic treatment prescribing among PwID receiving multiple forms of anti-psychotic treatment, and monitor variation between services (sites) and patient groups (e.g. psychiatric co-morbidities; challenging behaviour).

    Phase

    N/A

    Span

    19 weeks

    Sponsor

    University of Plymouth

    Redruth

    Recruiting

1-4 of 4